BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, July 15, 2025
See today's BioWorld Asia
Home
» Ji Xing acquires rights to heart failure treatment from Cytokinetics in $400M deal
To read the full story,
subscribe
or
sign in
.
Ji Xing acquires rights to heart failure treatment from Cytokinetics in $400M deal
Dec. 28, 2021
By
Doris Yu
RTW Investments LP-backed Ji Xing Pharmaceuticals Ltd. has acquired greater China rights to Cytokinetics Inc.’s omecamtiv mecarbil in a deal worth up to $400 million.
BioWorld Asia
Deals and M&A
Cardiovascular
China